Navigation Links
Cardio Vascular Medical Device Sends Update to Shareholders
Date:10/26/2009

HAIFA, Israel, October 26 /PRNewswire-FirstCall/ -- Cardio Vascular Medical Device Corp. (OTC: CVSL), a leading developer of advanced cardiovascular surgery technology, today released a brief shareholders update.

Cardio Vascular Medical Device holds a US patent for an innovative next-generation "steerable guidewire" applicable for all angioplasty (PCTA) procedures. The guidewire has a unique opportunity to become the guidewire of choice for surgeons throughout the world.

The technology hinges on a bendable tip that improves guidewire performance, enables faster procedure completion, and provides cost benefits for patients as well as healthcare providers.

"Cardio Vascular Medical Device has developed a technology that provides several advantages over the current guidewires being employed in angioplasty procedures," stated Eli Gonen, CEO of Cardio Vascular Medical Device Corp. "And with well over 7 million angioplasties performed each year, the global annual potential addressable market in excess of $500 million."

Cardio Vascular Medical Device is working diligently to complete the development of the guidewire, in preparation for full commercial distribution.

Cardio Vascular Medical Device Corp. plans to keep public shareholders informed of all upcoming company developments.

Forward-Looking Statements

This letter contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain, based on current expectations and assumptions concerning future events or future performance of Cardio Vascular Medical Device Corp. and its technologies. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release, as actual res
'/>"/>

SOURCE Cardio Vascular Medical Device Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Local Medicare Contractors Expand Hypertension Coverage for CardioDynamics BioZ(R) ICG Technology
2. CardioFocus Endoscopic Ablation System Earns CE Mark to Treat Atrial Fibrillation; US Clinical Investigation Underway
3. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
4. Boston Scientific Announces Schedule for European Society of Cardiology Congress 2007
5. Terumo Heart to Announce Results of European Clinical Trial of DuraHeart(TM) LVAS at European Association of Cardiothoracic Surgeons Meeting in September
6. ACTOS(R) (pioglitazone HCl) Demonstrates Reduced Risk of Ischemic Cardiovascular Disease in Patients with Type 2 Diabetes
7. Cleveland Clinic Summits to Focus on Cardiovascular Medical Innovation
8. Anthera Announces Completion of Enrollment and Dosing in Phase II Trial of A-002 for the Treatment of Cardiovascular Disease
9. Anthera Announces Positive Phase II Clinical Results From A-002 Cardiovascular Disease Trial
10. Cardiologists Tackle Next Frontier in Cardiovascular Disease
11. Enrollment of Women in Cardiovascular Trials Fails to Meet Current Federal Mandates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... 2014 According to a new ... (RFID) Market (Tags, Readers, Middleware, Printers and Cabinets) - ... 2014 - 2020" the global radiofrequency identification (RFID) market ... is expected to grow at a CAGR of 13.9% ... of USD 5.3 billion in 2020. Browse ...
(Date:8/28/2014)... PITTSBURGH , Aug. 28, 2014 /PRNewswire-iReach/ -- ... exhibiting at the 9 th Annual Global ... , September 8-9 th . The Global ... industry leaders in small molecule and biologic pharmaceutical ... address challenges that today,s manufacturers face, such as ...
(Date:8/28/2014)... , Aug. 28, 2014  Stryker Orthopaedics, the Official Joint ... bringing its message of joint health to golf fans at ... at the Deutsche Bank Championship. The company,s fan destination – ... Fan Zone on 9" at the TPC Boston in ... th .    At the Deutsche Bank Championship, ...
Breaking Medicine Technology:Radiofrequency Identification (RFID) Market in Healthcare is Expected to Reach USD 5.3 Billion Globally by 2020: Transparency Market Research 2Radiofrequency Identification (RFID) Market in Healthcare is Expected to Reach USD 5.3 Billion Globally by 2020: Transparency Market Research 3Radiofrequency Identification (RFID) Market in Healthcare is Expected to Reach USD 5.3 Billion Globally by 2020: Transparency Market Research 4Radiofrequency Identification (RFID) Market in Healthcare is Expected to Reach USD 5.3 Billion Globally by 2020: Transparency Market Research 5Gateway Analytical to Promote Particulate Identification Services at the 9th Annual Global Pharma Manufacturing Summit 2Gateway Analytical to Promote Particulate Identification Services at the 9th Annual Global Pharma Manufacturing Summit 3Stryker, Official Joint Replacement Products Of The PGA TOUR, Heads To Boston For The Deutsche Bank Championship 2Stryker, Official Joint Replacement Products Of The PGA TOUR, Heads To Boston For The Deutsche Bank Championship 3Stryker, Official Joint Replacement Products Of The PGA TOUR, Heads To Boston For The Deutsche Bank Championship 4Stryker, Official Joint Replacement Products Of The PGA TOUR, Heads To Boston For The Deutsche Bank Championship 5
... 11 CEL-SCI Corporation (NYSE CVM), a ... for the prevention and treatment of infectious diseases, announced today ... manufacturing equipment at its GMP manufacturing facility in Maryland. Completion ... it allows CEL-SCI to move forward with its drug manufacturing ...
... ... , , , , BOTHELL, Wash., Jan. 11 ... in automated external defibrillator ( AED ) and diagnostic cardiac monitoring devices, has ... development and commercialization of simple, cost-effective medical products and services that positively impact ...
Cached Medicine Technology:CEL-SCI Completes Validation of Manufacturing Facility Allowing It To Commence Manufacturing of Multikine 2CEL-SCI Completes Validation of Manufacturing Facility Allowing It To Commence Manufacturing of Multikine 3CEL-SCI Completes Validation of Manufacturing Facility Allowing It To Commence Manufacturing of Multikine 4Cardiac Science and Gust Bardy, MD Create Innovation Center for Primary Care Medicine 2Cardiac Science and Gust Bardy, MD Create Innovation Center for Primary Care Medicine 3Cardiac Science and Gust Bardy, MD Create Innovation Center for Primary Care Medicine 4Cardiac Science and Gust Bardy, MD Create Innovation Center for Primary Care Medicine 5Cardiac Science and Gust Bardy, MD Create Innovation Center for Primary Care Medicine 6Cardiac Science and Gust Bardy, MD Create Innovation Center for Primary Care Medicine 7
(Date:8/28/2014)... A fortuitous collaboration at Rice University has led ... natural antibiotic. , The laboratory recreation of a ... the fight against bacteria that evolve resistance to ... , As part of the process, Rice ... Shamoo and their colleagues created and tested a ...
(Date:8/28/2014)... nerves with adhesives, most researchers place glue directly on ... the nerve ends well and allows glue to easily ... However, it is difficult to insert the nerve ends ... there is frictional resistance. Xiangdang Liang and co-workers from ... conduit for the adhesive technique and defined the best ...
(Date:8/28/2014)... can be treated with nasal septum cells. Researchers at ... that cells taken from the nasal septum are able ... and can thus repair articular cartilage defects. The nasal ... joint environment is associated with the expression of so-called ... has published the research results together with the ...
(Date:8/28/2014)... every 200 Ontarians has been diagnosed with inflammatory bowel ... the disease increasing by 64 per cent between 1999 ... the Institute for Clinical Evaluative Sciences (ICES), the Children,s ... Research Institute. That puts Ontario in the 90th percentile ... published this week in Inflammatory Bowel Diseases , ...
(Date:8/28/2014)... seven per cent of rheumatoid arthritis patients in the ... as anti-TNF therapies did not take them as prescribed ... Infirmary were among those from 60 hospitals around the ... Arthritis Research UK Centre for Genetics and Genomics at ... that failure to take the drugs correctly, known as ...
Breaking Medicine News(10 mins):Health News:Synthesis produces new antibiotic 2Health News:Synthesis produces new antibiotic 3Health News:Synthesis produces new antibiotic 4Health News:From nose to knee: Engineered cartilage regenerates joints 2Health News:Ontario has one of the highest rates of IBD in the world 2Health News:Arthritis patients failing to take expensive medication, according to new research 2
... the malaria parasites to attack the red blood cells. ... Cell, will help the scientists in designing vaccines against ... through which malaria parasites invade red blood cells is ... merozoites called EBA-175 to a receptor protein on the ...
... a smart bomb for cancer treatment is to be reported ... into the tumor, seal the opening and then deliver ... This will leave the healthy cells unharmed. ,The ... cancer have the potential of being a revolutionary form of ...
... those people suffering from tension-headaches, acupuncture may be the ... journal BMJ said that acupuncture can reduce the incidence ... - the gold standard of clinical trials - researchers ... of tension headache into three groups. ,Over ...
... delays healing of physical wounds, a new study says//. ... of Illinois at Chicago in a study of laboratory ... delayed the closing of wounds by more than 45 ... of cell and genetic changes accounted for the slow ...
... and happen even when people are not aware of their ... 2005 issue of Nature. ,Researchers from University of California, ... Affairs Health System had undertaken the study to find out ... when they are actually not aware of doing so. ...
... A new study by scientists in Japan may help ... UPI. ,Richard Smith, a research professor in otolaryngology ... University gave a genetically deafened mouse interfering RNA (Ribonucleic ... that would otherwise cause deafness. ,"By preventing its ...
Cached Medicine News:Health News:Researchers Discover Protein That Causes Malaria 2Health News:An Anti-cancer Smart Bomb delivered using a Nanocell 2Health News:An Anti-cancer Smart Bomb delivered using a Nanocell 3Health News:Acupuncture May Be An Effective Treatment Against Tension-Headaches 2Health News:Habit Memory May Enhance Learning In People 2
... products for autoimmune testing feature single-well ANA ... as specific reflex tests including dsDNA, and ... (Ro), SS-B (La), Scl-70 and Jo-1. In ... full line of products for Cardiolipins (IgA, ...
... Our ELISA products for autoimmune testing feature ... as well as specific reflex tests including ... Sm/RNP, SS-A (Ro), SS-B (La), Scl-70 and ... includes a full line of products for ...
... products for autoimmune testing feature single-well ANA ... as specific reflex tests including dsDNA, and ... (Ro), SS-B (La), Scl-70 and Jo-1. In ... full line of products for Cardiolipins (IgA, ...
... is a leading provider of immunofluorescence assays, ... menu that includes kits for autoimmune diseases, ... miscellaneous conjugates and components. Our Impact IFA ... of substrates and kit sizes to choose ...
Medicine Products: